Six months after liver transplantation, David noticed his blood pressure climbing despite feeling “otherwise well.” Tacrolimus levels were therapeutic, renal function stable, yet systolic pressures remained above 150 mmHg. His transplant team chose amlodipine—not because it was the strongest drug, but because it worked with his new liver rather than against it.
Within weeks, his blood pressure normalized without worsening kidney function or destabilizing immunosuppressant levels. This quiet success reflects why amlodipine is so frequently selected in transplant medicine [3].
- Blocks L-type calcium channels in vascular smooth muscle
- Promotes arterial vasodilation with minimal cardiac depression
- Counters calcineurin-inhibitor–induced vasoconstriction
- Long half-life enables once-daily dosing without reflex tachycardia
Unlike non-dihydropyridine calcium-channel blockers, amlodipine has minimal direct effect on cardiac conduction, making it safer in transplant patients [1].
| Clinical Context | Recommended Dose | Key Notes |
|---|---|---|
| Early post-transplant | 2.5 mg daily | Avoid hypotension; monitor tacrolimus |
| Stable outpatient | 5 mg daily | Most common maintenance dose |
| Resistant hypertension | Up to 10 mg daily | Assess edema; consider add-on therapy |
| Drug | Interaction | Clinical Action |
|---|---|---|
| Tacrolimus | CYP3A4 inhibition may increase levels | Check troughs after initiation |
| Cyclosporine | Increased exposure possible | Monitor renal function closely |
| Azole antifungals | Potent CYP3A4 inhibition | Lower amlodipine dose |
| Class | Role Post-LT | Limitations |
|---|---|---|
| CCBs (Amlodipine) | First-line | Edema |
| ACE-I / ARB | Delayed use | Hyperkalemia |
| Beta-blockers | Adjunct | Fatigue |
- Confirm cause (CNI effect, volume, renal status)
- Start amlodipine 2.5–5 mg
- Monitor BP, edema, tacrolimus
- Add ACE-I/ARB only after renal stability
- Escalate or consult if resistant